named programs · 3 · from sources
What they call their work
Post-Herpetic Neuralgia Information Initiative
Disseminates information about long-term nerve pain following shingles, including risk factors and management
Shingles Public Awareness Campaign
Offers educational resources on shingles causes, symptoms, treatment, and prevention for the general public
Shingrix Vaccine Education
Provides detailed FAQs and scientific information about the Shingrix vaccine, including efficacy, dosing, side effects, and CDC recommendations
activities · 2 groups
What they do
-
Disease-Specific Clinical & Patient Education 1 activity
- Provides public health information on varicella-zoster virus infectionsOffers population-based educational resources to the public and healthcare providers about shingles, chickenpox, and related conditions, including vaccine efficacy and clinical guidance for vaccination.
-
-
Biomedical Research and Innovation 1 activity
- Supports research and education on varicella-zoster virus and related infectionsConducts and funds research initiatives and educational programs focused on the varicella-zoster virus, including chickenpox, shingles, and post-herpetic neuralgia. This includes organizing conferences and providing grants to advance scientific understanding and public health responses.
-
financials · form 990EZ · fy2024
revenue
Total revenue$17K
Contributions & grants$17K100%
Program service revenue——
Investment income$270%
Other revenue—
expenses
Total expenses$183K
Program expenses77%
Admin / overhead19%
Fundraising4%
Salaries & benefits$101K
Grants paid out$5K
Largest expense lineCompensation
balance sheet
Total assets$117K
Cash$490K
Investments$0
Liabilities$3K
Net assets$116K
Liquid reserves32.1 mo
6 years on record · 2019–2024 · YoY revenue -91.2%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 2
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| LOUIS R GARY | CEO, DIRECTOR | 32 | $92K |
| JOHN E KITTLE | PRESIDENT,DIRECTOR | 32 | $4K |
board members · 5
- CAROL UELAND — CO-SEC,CO-TR,DIRECTOR
- CHARLOTTE FORD — DIRECTOR
- CRAIG JACOBS — DIRECTOR
- LIEF D ROSENBLATT — DIRECTOR
- RICHARD N PODELL — DIRECTOR
relationships · 6
Who they work with
- CDC Government — Relies on CDC guidelines and recommendations for Shingrix administration and policy, including dosing intervals and use in immunocompromised individuals.
- Centers for Disease Control Government — References CDC's acceptance of ACIP recommendations on Shingrix vaccine.
- GSK Partner — References GSK as the manufacturer of Shingrix and cites its clinical data and product information in educational materials.
- GSK Partner — References Shingrix vaccine developed by GSK for shingles prevention.
- Merck Partner — References Merck’s Zostavax vaccine for comparative context regarding shingles vaccination history and transition guidance.
- Merck Partner — References Zostavax vaccine developed by Merck in context of shingles prevention.
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Early Diagnosis and Treatment Intervention 37 orgsmethodology: early_diagnosis_and_treatmentBy encouraging medical evaluation and antiviral treatment within 24 to 72 hours of rash onset, we reduce complications and severity of shingles because timely antiviral therapy limits viral replication and spread in neural tissues.shared approach: Education-for-Early-Detection →
- Integrated Research and Public Education Model 37 orgsmethodology: research_and_educationBy combining research dissemination with public education, conferences, and grant support, we advance prevention and treatment of shingles because sustained knowledge transfer improves clinical adoption, public awareness, and vaccine uptake.shared approach: Education-for-Early-Detection →
- Vaccination-Based Prevention and Upgrade Strategymethodology: recombinant_subunit_vaccinationBy promoting the use of Shingrix, a non-live recombinant subunit vaccine, for both initial and upgraded vaccination, we prevent shingles more effectively in older adults because it generates a stronger and safer immune response than live-virus vaccines like Zostavax, especially in immunocompromised or aging populations.